Handelsman Y, et al. – In this study involving 461 adults with uncontrolled type 2 diabetes, researchers compared the effectiveness and safety of triple therapy with dapagliflozin (DAPA) plus saxagliptin (SAXA) and metformin (MET) to dual therapy with sitagliptin (SITA) added to MET. They observed lower HbA1c concentrations in study participants in the DAPA+SAXA+MET group at weeks 26 and 52 vs those in the SITA+MET group. Overall, they noted better results with more durable glycemic control with the triple therapy (DAPA+SAXA+MET) vs the dual therapy (SITA+MET) in diabetic adults with high HbA1c levels that were not adequately controlled with MET monotherapy.